InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (16 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
16
T+90 hit rate
20%
T+90 mean return
-13.7%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Evans John M., Chairman & CEO. Director active across 1 company, notably Beam Therapeutics Inc.. Cumulatively, 32 filings have been published. Breakdown: 0 buy · 16 sells. Total volume traded: €9m. Activity tracked since 25 June 2021. The latest transaction was filed on 1 April 2025 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations32 total
18,663 sharesCommon StockSEC:0001193125-26-292526:0
6,337 sharesCommon StockSEC:0001193125-26-292526:1
13,421 sharesCommon StockSEC:0001193125-26-292526:2
11,579 sharesCommon StockSEC:0001193125-26-292526:3
25,000 sharesCommon StockSEC:0001193125-26-292526:4
23,100 sharesCommon StockSEC:0001193125-26-292526:5
1,900 sharesCommon StockSEC:0001193125-26-292526:6
30,663 shares@ US$18.35065.7% of flowCommon StockSEC:0000950170-25-050857:0
30,000 shares@ US$0.670.2% of flowCommon StockSEC:0000950170-25-049297:0
77,500 shares0Common StockSEC:0000950170-25-049759:0
29,800 shares@ US$26.74598.3% of flowCommon StockSEC:0000950170-25-012304:0
60,000 shares@ US$24.600414.4% of flowCommon StockSEC:0000950170-24-111732:0
60,000 shares@ US$24.502614.9% of flowCommon StockSEC:0000950170-24-079065:0
18,102 shares@ US$32.135.9% of flowCommon StockSEC:0000950170-24-041432:0
60,000 shares@ US$33.856720.4% of flowCommon StockSEC:0000950170-24-039319:0
60,000 shares@ US$25.3315.2% of flowCommon StockSEC:0000950170-24-010477:0
5,161 shares@ US$30.311.6% of flowCommon StockSEC:0000899243-23-010819:0
225 shares0Common StockSEC:0000899243-23-010137:0
7,567 shares@ US$44.92463.7% of flowCommon StockSEC:0000899243-22-034759:0
10,181 shares@ US$64.86887.0% of flowCommon StockSEC:0000899243-22-027077:0
12,246 shares@ US$7.220.0029% mcap34.6% of flowCommon StockSEC:0000899243-22-016164:0
56,250 shares0Common StockSEC:0000899243-22-013487:0
12,000 shares0Common StockSEC:0000899243-22-004197:0
12,000 shares0Common StockSEC:0000899243-22-004197
27,700 shares@ US$1.030.3% of flowCommon StockSEC:0000899243-21-039697
25 of 32 declarations
About Evans John M.
John M. Evans is the Chief Executive Officer of Beam Therapeutics Inc. He is responsible for the strategic direction of the company, which focuses on developing innovative gene therapies. Under his leadership, Beam Therapeutics is committed to transforming healthcare through gene-editing-based solutions. John brings deep expertise in biotechnology and management, contributing to advancing the company's mission to improve patients' lives.
